These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21343397)

  • 1. p95HER2 and breast cancer.
    Arribas J; Baselga J; Pedersen K; Parra-Palau JL
    Cancer Res; 2011 Mar; 71(5):1515-9. PubMed ID: 21343397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 fragmentation and breast cancer stratification.
    Arribas J; Parra-Palau JL; Pedersen K
    Clin Cancer Res; 2010 Aug; 16(16):4071-3. PubMed ID: 20682714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P95 HER2 fragments and breast cancer outcome.
    Tural D; Akar E; Mutlu H; Kilickap S
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1089-96. PubMed ID: 24968823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
    Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
    Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
    Sperinde J; Huang W; Vehtari A; Chenna A; Kellokumpu-Lehtinen PL; Winslow J; Bono P; Lie YS; Petropoulos CJ; Weidler J; Joensuu H
    Clin Cancer Res; 2018 Jul; 24(13):3046-3052. PubMed ID: 29535130
    [No Abstract]   [Full Text] [Related]  

  • 7. Polyclonal antibodies against gp185HER2 peptides: their putative role in the identification of a particular HER2 status in patients with breast cancer.
    Di Modugno F; Buglioni S; Mottolese M; Bello DD; Cascioli S; Chersi A; Santoni A; Nisticò P
    J Immunother; 2001; 24(3):221-31. PubMed ID: 11394499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers.
    Morancho B; Parra-Palau JL; Ibrahim YH; Bernadó Morales C; Peg V; Bech-Serra JJ; Pandiella A; Canals F; Baselga J; Rubio I; Arribas J
    Oncogene; 2013 Mar; 32(11):1452-9. PubMed ID: 22641219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
    J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.
    Growdon WB; Groeneweg J; Byron V; DiGloria C; Borger DR; Tambouret R; Foster R; Chenna A; Sperinde J; Winslow J; Rueda BR
    Gynecol Oncol; 2015 Apr; 137(1):160-6. PubMed ID: 25602714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic and therapeutic role of HER2 in cancer.
    Ménard S; Pupa SM; Campiglio M; Tagliabue E
    Oncogene; 2003 Sep; 22(42):6570-8. PubMed ID: 14528282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
    Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
    Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
    Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
    N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 signatures in breast cancer: ready to go to print?
    Eichhorn PJ; Baselga J
    J Clin Oncol; 2010 Apr; 28(11):1809-10. PubMed ID: 20231675
    [No Abstract]   [Full Text] [Related]  

  • 15. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.
    Anido J; Scaltriti M; Bech Serra JJ; Santiago Josefat B; Todo FR; Baselga J; Arribas J
    EMBO J; 2006 Jul; 25(13):3234-44. PubMed ID: 16794579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis.
    Pedersen K; Angelini PD; Laos S; Bach-Faig A; Cunningham MP; Ferrer-Ramón C; Luque-García A; García-Castillo J; Parra-Palau JL; Scaltriti M; Ramón y Cajal S; Baselga J; Arribas J
    Mol Cell Biol; 2009 Jun; 29(12):3319-31. PubMed ID: 19364815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
    Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
    Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.
    Serrano-Olvera A; Dueñas-González A; Gallardo-Rincón D; Candelaria M; De la Garza-Salazar J
    Cancer Treat Rev; 2006 May; 32(3):180-90. PubMed ID: 16483720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer.
    Tsé C; Gauchez AS; Jacot W; Lamy PJ
    Cancer Treat Rev; 2012 Apr; 38(2):133-42. PubMed ID: 21549508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.